Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - iBio, Inc. | tm2122365d1_8k.htm |
| EX-99.1 - EXHIBIT 99.1 - iBio, Inc. | tm2122365d1_ex99-1.htm |
Exhibit 99.2
Mice were immunized with iBio’s SARS-CoV-2 nucleocapsid (N) vaccine candidate in combination with several adjuvants, leading to robust and differentiated immune responses. Th-1 skewed N-specific antibody titers were observed in antigen/adjuvant combinations following intramuscular injection, notably Groups 4 and 7 (panel A). Robust T cell priming was measured by ELIspot for multiple antigen/adjuvant combinations (C and D, as examples), while immune cells from a naïve mouse showed no response to exposure to the N antigen (B).